Loading
A Swedish trial gave mebendazole to ten people with advanced bowel and stomach cancers that had stopped responding to treatment; it was safe, but every patient's cancer kept growing, four of them unusually fast.
Patients with treatment-refractory gastrointestinal cancer received mebendazole at individually adjusted doses up to 4 g a day aiming at a serum level of 300 ng/mL; 11 were included and 10 started treatment (Mebendazole phase 2a 2021). Two stopped before and the remaining eight after the eight-week CT scan, all for progressive disease, four met suggested criteria for hyperprogression, only five reached the target level, and no severe adverse effects were observed; the authors conclude that new approaches such as prodrugs or combinations would be needed for further exploration (Mebendazole phase 2a 2021).
The only completed efficacy study of an internet-famous dewormer in cancer patients found no benefit in anyone. It is the clearest human result in this whole story.
Shares Mebendazole, Systematic drug repurposing.
Shares Systematic drug repurposing, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
Shares Systematic drug repurposing, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
Shares Systematic drug repurposing, Gastric & gastro-oesophageal junction cancer.
Shares Mebendazole, Systematic drug repurposing, Single-arm trial.